Send to

Choose Destination
J Cell Sci. 2014 Apr 15;127(Pt 8):1672-83. doi: 10.1242/jcs.132316. Epub 2014 Feb 12.

Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression.

Author information

Harvard-MIT Division of Health Sciences and Technology, MIT, Cambridge, MA 02139, USA.


Although a number of growth factors and receptors are known to control tumor angiogenesis, relatively little is known about the mechanism by which these factors influence the directional endothelial cell migration required for cancer microvessel formation. Recently, it has been shown that the focal adhesion protein paxillin is required for directional migration of fibroblasts in vitro. Here, we show that paxillin knockdown enhances endothelial cell migration in vitro and stimulates angiogenesis during normal development and in response to tumor angiogenic factors in vivo. Paxillin produces these effects by decreasing expression of neuropilin 2 (NRP2). Moreover, soluble factors secreted by tumors that stimulate vascular ingrowth, including vascular endothelial growth factor (VEGF), also decrease endothelial cell expression of paxillin and NRP2, and overexpression of NRP2 reverses these effects. These results suggest that the VEGF-paxillin-NRP2 pathway could represent a new therapeutic target for cancer and other angiogenesis-related diseases.


Angiogenesis; Cancer; Capillary endothelial cell; Motility; Neuropilin 2; Paxillin; VEGF

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center